Literature DB >> 3304665

Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implants.

J Glowacki, J B Lian.   

Abstract

This is a report of an experimental system to study differentiation of bone-resorbing osteoclasts and demonstrates that osteocalcin, an extracellular bone-specific component, is necessary for the recruitment of osteoclast progenitor cells. The subcutaneous implantation of devitalized bone particles (BPs) elicits the recruitment and differentiation of osteoclasts that resorb the BPs. In a previous study, we showed by histomorphometric analysis that BPs that were deficient in osteocalcin were resorbed only 60% as well as normal BPs. In this study, the mechanism of this difference was investigated by measurements of recruitment, differentiation and activity of bone resorbing cells by normal and osteocalcin-deficient BP. Mononuclear cells were attracted to control BPs soon after implantation. In dramatic contrast, cellularity was depressed around osteocalcin-deficient BPs with very few mononuclear cells within the implant on day 5 (35% of control cellularity). In implants of normal BPs, tartrate-resistant acid phosphatase-positive multinucleated cells were evident by day 5; very few appeared in implants of osteocalcin-deplete BPs even by day 12. The amount of tartrate-resistant acid phosphatase activity in homogenates of the osteocalcin-deficient bone particle specimens not only lagged behind controls but never reached the maximum activity of control BP specimens. These data support the hypothesis that osteocalcin may function as a matrix signal in the recruitment and/or activation of cells for bone resorption.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304665     DOI: 10.1016/0045-6039(87)90479-9

Source DB:  PubMed          Journal:  Cell Differ        ISSN: 0045-6039


  27 in total

1.  Osteoclast formation is related to bone matrix age.

Authors:  B Groessner-Schreiber; M Krukowski; D Hertweck; P Osdoby
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

Review 2.  An overview of osteocalcin progress.

Authors:  Jinqiao Li; Hongyu Zhang; Chao Yang; Yinghui Li; Zhongquan Dai
Journal:  J Bone Miner Metab       Date:  2016-01-08       Impact factor: 2.626

Review 3.  A four-season molecule: osteocalcin. Updates in its physiological roles.

Authors:  Giovanni Lombardi; Silvia Perego; Livio Luzi; Giuseppe Banfi
Journal:  Endocrine       Date:  2014-08-27       Impact factor: 3.633

Review 4.  Diagnostic biomarkers for oral and periodontal diseases.

Authors:  Mario Taba; Janet Kinney; Amy S Kim; William V Giannobile
Journal:  Dent Clin North Am       Date:  2005-07

5.  Induction of osteocalcin gene expression in vitro by progesterone.

Authors:  L Chen; N T Foged
Journal:  J Tongji Med Univ       Date:  1997

6.  Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression.

Authors:  J Lian; C Stewart; E Puchacz; S Mackowiak; V Shalhoub; D Collart; G Zambetti; G Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  The Sox2 high mobility group transcription factor inhibits mature osteoblast function in transgenic mice.

Authors:  Greg Holmes; Timothy G Bromage; Claudio Basilico
Journal:  Bone       Date:  2011-06-15       Impact factor: 4.398

Review 8.  Development of the osteoblast phenotype: molecular mechanisms mediating osteoblast growth and differentiation.

Authors:  J B Lian; G S Stein
Journal:  Iowa Orthop J       Date:  1995

9.  Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.

Authors:  P Szulc; M C Chapuy; P J Meunier; P D Delmas
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Age- and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. Possible involvement of osteocalcin in bone remodeling.

Authors:  R T Ingram; Y K Park; B L Clarke; L A Fitzpatrick
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.